Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
